Volume 23, Number 2—February 2017
Dispatch
Increasing Antibiotic Resistance in Shigella spp. from Infected New York City Residents, New York, USA
Kenya Murray, Vasudha Reddy, John Kornblum, HaeNa Waechter, Ludwin F. Chicaiza, Inessa Rubinstein, Sharon Balter, Sharon K. Greene, Sarah L. Braunstein, Jennifer L. Rakeman, and Catherine M. Dentinger
Table 1
Shigella case-patient characteristics, by azithromycin or ciprofloxacin resistance, New York City, New York, USA, March 22, 2013–May 31, 2015*
| Characteristic | No. (%) case-patients |
|||
|---|---|---|---|---|
| DSA, n = 129 | Ciprofloxacin resistant, n = 29 | Susceptible, n = 530 | Total, n = 683† | |
| Male sex |
120 (93) |
22 (76) |
306 (58) |
446 (65) |
| Age, y | ||||
| 0–17 | 3 (2) | 7 (24) | 254 (48) | 262 (38) |
| 18–64 | 119 (92) | 19 (66) | 261 (49) | 397 (58) |
| >65 |
7 (5) |
3 (10) |
15 (3) |
24 (4) |
| Race | ||||
| White | 58 (45) | 12 (41) | 107 (20) | 174 (25) |
| Black | 39 (30) | 1 (3) | 75 (14) | 115 (17) |
| Other | 3 (2) | 4 (14) | 11 (2) | 17 (2) |
| Unknown |
29 (22) |
12 (41) |
337 (64) |
377 (55) |
| Ethnicity | ||||
| Hispanic | 15 (12) | 3 (10) | 74 (14) | 91 (13) |
| Non-Hispanic | 78(60) | 15 (52) | 131 (25) | 222 (33) |
| Unknown |
36(28) |
11(38) |
325 (61) |
370 (54) |
| Borough | ||||
| Bronx | 19 (15) | 1 (3) | 100 (19) | 120 (18) |
| Brooklyn | 32 (25) | 7 (24) | 192 (36) | 230 (34) |
| Manhattan | 61 (47) | 12 (41) | 119 (22) | 191 (28) |
| Queens | 16 (12) | 7 (24) | 111 (21) | 131 (19) |
| Staten Island |
1 (1) |
2 (7) |
8 (2) |
11 (2) |
| Neighborhood poverty, %‡ | ||||
| <10 | 23 (18) | 8 (29) | 87 (17) | 117 (18) |
| 10–<20 | 48 (38) | 10 (36) | 137 (27) | 195 (29) |
| 20–<30 | 37 (29) | 7 (25) | 111 (22) | 152 (23) |
| 30–100 |
20 (16) |
3 (11) |
176 (34) |
199 (30) |
| HIV diagnosed |
76 (59) |
7 (24) |
101 (19) |
183 (27) |
| Antibiotic resistance by species§ | ||||
| S. sonnei | 42 (33) | 23 (79) | 381 (72) | 443 (65) |
| DSA | 42 (100) | 3 (13) | 381(100) | 42 (9) |
| Ciprofloxacin | 3 (7) | 23 (100) | 380 (100)§ | 23 (5) |
| Ampicillin | 39 (93) | 4 (17) | 177 (46) | 218 (49) |
| Cefixime | 1 (1) | 2 (9) | 4 (1) | 6 (1) |
| TMP/SMX | 37 (88) | 20 (87) | 252 (66) | 308 (70) |
| S. flexneri | 86 (67) | 5 (17) | 140 (26) | 230 (34) |
| DSA | 86 (100) | 1 (20) | 140 (100) | 86 (37) |
| Ciprofloxacin | 1 (1) | 5 (100) | 139 (100)§ | 5 (2) |
| Ampicillin | 79 (92) | 5 (100) | 109 (78) | 192 (83) |
| Cefixime | 2 (2) | 1 (20) | 1(1) | 3 (1) |
| TMP/SMX | 73 (85) | 4 (80) | 89 (64) | 166 (72) |
*N = 683 sporadic cases. DSA, decreased susceptibility to azithromycin; TMP/SMX, trimethoprim/sulfamethoxazole.
†5 isolates resistant to ciprofloxacin also displayed DSA.
‡Percentage of residents census tract below federal poverty level, per American Community Survey, 2009–2013; 19 missing.
§S. boydii (n = 7) and S. dysenteriae (n = 3) omitted.
Page created: January 17, 2017
Page updated: January 17, 2017
Page reviewed: January 17, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.